TY - JOUR
T1 - Experiences of general practitioners explaining central sensitisation to patients with persistent physical symptoms
T2 - A focus group study
AU - den Boer, Carine
AU - Terluin, Berend
AU - van der Wouden, Johannes C.
AU - Blankenstein, Annette H.
AU - van der Horst, Henriëtte E.
N1 - Publisher Copyright:
© 2022 BMJ Publishing Group. All rights reserved.
PY - 2022/7/26
Y1 - 2022/7/26
N2 - Objective Patients with persistent physical symptoms (PPS) require an explanation that is acceptable and comprehensible to them. Central sensitisation (CS) is an explanatory model for PPS and chronic pain that has been broadly applied in the context of pain medicine, but, until recently, not by general practitioners (GPs). We explored how GPs used the CS model in their consultations with patients with PPS. Design and setting A qualitative focus group study among GPs in the Netherlands. Methods We instructed 33 GPs on how to explain CS to patients with PPS. After 0.5-1.5 years of using the CS model, 26 GPs participated in focus groups and interviews to report and discuss their experiences with CS as an explanatory model. Audio recordings were transcribed and two researchers independently analysed the data. The text was coded, codes were organised into themes and discussed until consensus was reached. Results We identified eleven themes and grouped these into four categories. The GPs regarded the CS model as evidence-based, credible and giving recognition to the patient. On the other hand, they found explaining the CS model difficult and time-consuming. They tailored the CS model to their patients' needs and used multiple consultations to explain the model. The GPs reported that the use of the CS model seemed to improve the understanding and acceptance of the symptoms by the patients and seemed to reduce their need for more diagnostic tests. Furthermore, patients seemed to become more motivated to accept appropriate therapy. Conclusion GPs reported that they were able to provide explanations with the CS model to their patients with PPS. They regarded the model as evidence-based, credible and giving recognition to the patient, but explaining it difficult and time-consuming.
AB - Objective Patients with persistent physical symptoms (PPS) require an explanation that is acceptable and comprehensible to them. Central sensitisation (CS) is an explanatory model for PPS and chronic pain that has been broadly applied in the context of pain medicine, but, until recently, not by general practitioners (GPs). We explored how GPs used the CS model in their consultations with patients with PPS. Design and setting A qualitative focus group study among GPs in the Netherlands. Methods We instructed 33 GPs on how to explain CS to patients with PPS. After 0.5-1.5 years of using the CS model, 26 GPs participated in focus groups and interviews to report and discuss their experiences with CS as an explanatory model. Audio recordings were transcribed and two researchers independently analysed the data. The text was coded, codes were organised into themes and discussed until consensus was reached. Results We identified eleven themes and grouped these into four categories. The GPs regarded the CS model as evidence-based, credible and giving recognition to the patient. On the other hand, they found explaining the CS model difficult and time-consuming. They tailored the CS model to their patients' needs and used multiple consultations to explain the model. The GPs reported that the use of the CS model seemed to improve the understanding and acceptance of the symptoms by the patients and seemed to reduce their need for more diagnostic tests. Furthermore, patients seemed to become more motivated to accept appropriate therapy. Conclusion GPs reported that they were able to provide explanations with the CS model to their patients with PPS. They regarded the model as evidence-based, credible and giving recognition to the patient, but explaining it difficult and time-consuming.
KW - MENTAL HEALTH
KW - PAIN MANAGEMENT
KW - PRIMARY CARE
UR - http://www.scopus.com/inward/record.url?scp=85135111368&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2021-060063
DO - 10.1136/bmjopen-2021-060063
M3 - Article
C2 - 35882464
SN - 2044-6055
VL - 12
JO - BMJ Open
JF - BMJ Open
IS - 7
M1 - e060063
ER -